Recombinant norovirus-specific scFv inhibit virus-like particle binding to cellular ligands
Open Access
- 1 January 2008
- journal article
- Published by Springer Nature in Virology Journal
- Vol. 5 (1) , 21
Abstract
Noroviruses cause epidemic outbreaks of gastrointestinal illness in all age-groups. The rapid onset and ease of person-to-person transmission suggest that inhibitors of the initial steps of virus binding to susceptible cells have value in limiting spread and outbreak persistence. We previously generated a monoclonal antibody (mAb) 54.6 that blocks binding of recombinant norovirus-like particles (VLP) to Caco-2 intestinal cells and inhibits VLP-mediated hemagglutination. In this study, we engineered the antigen binding domains of mAb 54.6 into a single chain variable fragment (scFv) and tested whether these scFv could function as cell binding inhibitors, similar to the parent mAb.The scFv54.6 construct was engineered to encode the light (VL) and heavy (VH) variable domains of mAb 54.6 separated by a flexible peptide linker, and this recombinant protein was expressed in Pichia pastoris. Purified scFv54.6 recognized native VLPs by immunoblot, inhibited VLP-mediated hemagglutination, and blocked VLP binding to H carbohydrate antigen expressed on the surface of a CHO cell line stably transfected to express alpha 1,2-fucosyltransferase.scFv54.6 retained the functional properties of the parent mAb with respect to inhibiting norovirus particle interactions with cells. With further engineering into a form deliverable to the gut mucosa, norovirus neutralizing antibodies represent a prophylactic strategy that would be valuable in outbreak settings.Keywords
This publication has 37 references indexed in Scilit:
- Norovirus protein structure and functionFEMS Microbiology Letters, 2005
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Are Noroviruses Emerging?Emerging Infectious Diseases, 2005
- Norovirus disease: changing epidemiology and host susceptibility factorsTrends in Microbiology, 2004
- Human susceptibility and resistance to Norwalk virus infectionNature Medicine, 2003
- Therapeutic antibodies for human diseases at the dawn of the twenty-first centuryNature Reviews Drug Discovery, 2003
- Norwalk Virus-Like Particle Hemagglutination by Binding to H Histo-Blood Group AntigensJournal of Virology, 2003
- Binding of Norwalk Virus-Like Particles to ABH Histo-Blood Group Antigens Is Blocked by Antisera from Infected Human Volunteers or Experimentally Vaccinated MiceJournal of Virology, 2002
- Norwalk Virus Infection and Disease Is Associated with ABO Histo–Blood Group TypeThe Journal of Infectious Diseases, 2002
- X-ray Crystallographic Structure of the Norwalk Virus CapsidScience, 1999